Merck has announced early results from trials done on mulnupiravir, an influenza drug, that show it reduces the time it takes for COVID-19 positive individuals to test negative after having symptoms associated with the disease. From a 200 participant trial, the group receiving mulnupiravir had no members showing viral loads after 5 days, while the group receiving placebo saw 24% of members with viral loads.